Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Primary Biliary Cirrhosis

  • Chapter
Clinical Hepatology

  • 1837 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abdulkarim AS, Petrovic LM, Kim WR, et al (2004) Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol 40: 380–4

    Article  PubMed  Google Scholar 

  2. Ahrens EH Jr, Payne MA, Kunkel HG, et al (1950) Primary biliary cirrhosis. Medicine (Baltimore) 29: 299–364

    Google Scholar 

  3. Ala A, Stanca CM, Bu-Ghanim M, et al (2006) Increased prevalence of primary biliary cirrhosis near superfund waste sites. Hepatology 43: 525–31

    Article  PubMed  Google Scholar 

  4. Angulo P, Batts KP, Therneau TM, et al (1999) Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29: 644–7

    Article  CAS  PubMed  Google Scholar 

  5. Angulo P, Jorgensen RA, Keach JC, et al (2000) Oral budes-onide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31: 318–23

    Article  CAS  PubMed  Google Scholar 

  6. Bach N, Thung SN, Schaffner F (1998) The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med 122: 342–5

    CAS  PubMed  Google Scholar 

  7. Bach N, Bodian C, Bodenheimer H, et al (2003) Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 98: 187–93

    Article  CAS  PubMed  Google Scholar 

  8. Blackburn P, Freeston M, Baker CR, et al (2007) The role of psychological factors in the fatigue of primary biliary cirrhosis. Liver Int 27: 654–61

    Article  PubMed  Google Scholar 

  9. Browning J, Combes B, Mayo MJ (2003) Long-term effi-cacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 98: 2736–41

    Article  CAS  PubMed  Google Scholar 

  10. Burroughs AK, Butler P, Sternberg MJ, et al (1992) Molecular mimicry in liver disease. Nature 358: 377–8

    Article  CAS  PubMed  Google Scholar 

  11. Christensen E, Neuberger J, Crowe J, et al (1985) Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 89: 1084–91

    CAS  PubMed  Google Scholar 

  12. Combes B, Emerson SS, Flye NL, et al (2005) Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42: 1184–93

    Article  CAS  PubMed  Google Scholar 

  13. Combes B, Luketic VA, Peters MG, et al (2004) Prolonged follow-up of patients in the U.S. multicenter trial of ursode-oxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 99: 264–8

    Article  CAS  PubMed  Google Scholar 

  14. Combes B, Markin RS, Wheeler DE, et al (1999) The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 30: 602–5

    Article  CAS  PubMed  Google Scholar 

  15. Corpechot C, Carrat F, Bonnand AM, et al (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32: 1196–9

    Article  CAS  PubMed  Google Scholar 

  16. Corpechot C, Carrat F, Bahr A, et al (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128: 297–303

    Article  CAS  PubMed  Google Scholar 

  17. Dahlan Y, Smith L, Simmonds D, et al (2003) Pediatric-onset primary biliary cirrhosis. Gastroenterology 125: 1476–9

    Article  PubMed  Google Scholar 

  18. Davern TJ, Lake JR (1998) Recurrent disease after liver transplantation. Semin Gastrointest Dis 9: 86–109

    CAS  PubMed  Google Scholar 

  19. Degott C, Zafrani ES, Callard P, et al (1999) Histopatho-logical study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29: 1007–12

    Article  CAS  PubMed  Google Scholar 

  20. Dickson E, Grambsch PM, Fleming TR, et al (1989) Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10: 1–7

    Article  CAS  PubMed  Google Scholar 

  21. Dilger K, Cascorbi I, Grunhage F, et al (2006) Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int 26: 285–90

    Article  CAS  Google Scholar 

  22. Farrell DJ, Hines JE, Walls AF, et al (1995) Intrahepatic mast cells in chronic liver diseases. Hepatology 22: 1175–81

    CAS  PubMed  Google Scholar 

  23. Forton DM, Patel N, Prince M, et al (2004) Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 53: 587–92

    Article  CAS  PubMed  Google Scholar 

  24. Galperin C, Gershwin ME (1996) Immunopathology of primary biliary cirrhosis. Baillieres Clin Gastroenterol 10: 461–81

    Article  CAS  PubMed  Google Scholar 

  25. Gershwin ME, Mackay IR, Sturgess A, et al (1987) Identi-fication and specificity of a cDNA encoding the 70 kd mito-chondrial antigen recognized in primary biliary cirrhosis. J Immunol 138: 3525–31

    CAS  PubMed  Google Scholar 

  26. Gershwin ME, Selmi C, Worman HJ, et al (2005) Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology 42: 1194–202

    Article  PubMed  Google Scholar 

  27. Gershwin EM, Mackay IR (2008) The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47: 737–45

    Article  PubMed  Google Scholar 

  28. Gong Y, Huang Z, Christensen E, et al (2007) Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using bayesian approach as sensitivity analyses. Am J Gastroenterol 102: 1799–807

    Article  CAS  PubMed  Google Scholar 

  29. Gong Y, Klingenberg SL, Gluud C (2006) Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis–Cochrane Hepato-Biliary Group. Aliment Pharmacol Ther 24: 1535–44

    Article  CAS  PubMed  Google Scholar 

  30. Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354: 1053–60

    Article  CAS  PubMed  Google Scholar 

  31. Granito A, Muratori P, Muratori L, et al (2006) Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/ membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther 24: 1575–83

    Article  CAS  PubMed  Google Scholar 

  32. Guanabens N, Parés A, Ros I, et al (2003) Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98: 2268–74

    CAS  PubMed  Google Scholar 

  33. Heathcote EJ (2000) AASLD guideline: management of primary biliary cirrhosis. Hepatology 31: 1005–13

    Article  CAS  PubMed  Google Scholar 

  34. Hempfling W, Grunhage F, Dilger K, et al (2003) Pharma-cokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38: 196–202

    Article  CAS  PubMed  Google Scholar 

  35. Hendrickse M, Rigney E, Giaffer MH, et al (1999) Low-dose methotrexate in primary biliary cirrhosis: long-term results of a placebo controlled trial. Gastroenterology 117: 400–7

    Article  CAS  PubMed  Google Scholar 

  36. Hodgson SF, Dickson ER, Wahner HW, et al (1985) Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103: 855–60

    CAS  PubMed  Google Scholar 

  37. Invernizzi P, Podda M, Battezzati PM, et al (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34: 366–72

    Article  CAS  PubMed  Google Scholar 

  38. Invernizzi P, Selmi C, Mackay IR, et al (2005) From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenetrol Hepatol 3: 401–10

    Article  CAS  Google Scholar 

  39. Jackson H, Solaymani-Dodaran M, Card TR, et al (2007) Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 46: 1131–7

    Article  CAS  PubMed  Google Scholar 

  40. James OFW, Bhopal R, Howel D, et al (1999) Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 30: 390–4

    Article  CAS  PubMed  Google Scholar 

  41. Janka C, Selmi C, Gershwin ME, et al (2005) Small ubiq-uitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology 41: 609–16

    Article  CAS  PubMed  Google Scholar 

  42. Jones DEJ, Metcalf J V, Collier JD, et al (1997) Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26: 1138–42

    Article  CAS  PubMed  Google Scholar 

  43. Jones DEJ, Bhala N, Burt J, et al (2006) Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55: 536–541

    Article  CAS  PubMed  Google Scholar 

  44. Jones DEJ (2007) Pathogenesis of primary biliary cirrhosis. Gut 56: 1615–24

    CAS  PubMed  Google Scholar 

  45. Jones DEJ, Newton JL (2007) An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 25: 471–6

    Article  CAS  PubMed  Google Scholar 

  46. Jorgensen R, Angulo P, Dickson ER, et al (2002) Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterology 97: 2647–50

    Article  CAS  Google Scholar 

  47. Joshi S, Cauch-Dudek K, Heathcote J, et al (2002) Antimito-chondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 97: 999–1002

    Article  Google Scholar 

  48. Kaplan MM (1996) Primary biliary cirrhosis. N Engl J Med 335: 1570–80

    Article  CAS  PubMed  Google Scholar 

  49. Kaplan MM, Alling DW, Zimmerman HJ, et al (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315: 1448–54

    Article  CAS  PubMed  Google Scholar 

  50. Kaplan MM, Cheng S, Price LL, et al (2004) A randomized controlled trial of colchicine plus ursodiol versus methotrex-ate plus ursodiol in primary biliary cirrhosis: ten year results. Hepatology 39: 915–23

    Article  CAS  PubMed  Google Scholar 

  51. Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353: 1261–73

    Article  CAS  PubMed  Google Scholar 

  52. Kaplan MM, Schmid C, Provenzale D, et al (1999) A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 117: 1173–80

    Article  CAS  PubMed  Google Scholar 

  53. Kikuchi K, Lian ZX, Yang GX, et al (2005) Bacterial CpG induces hyper-IgM production in CD27+ memory B cells in primary biliary cirrhosis. Gastroenterology 128: 304–12

    Article  CAS  PubMed  Google Scholar 

  54. Kim WR, Wiesner RH, Therneau TM, et al (1998) Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 28: 33–8

    Article  CAS  PubMed  Google Scholar 

  55. Kim WR, Lindor KD, Locke III GR, et al (2000) Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gastroenterology 119: 1631–6

    Article  CAS  PubMed  Google Scholar 

  56. Kingham JG, Parker DR (1998) The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 42: 120–2

    Article  CAS  PubMed  Google Scholar 

  57. Koulentaki M, Ioannidou D, Stefanidou M, et al (2006) Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 101: 541–6

    Article  PubMed  Google Scholar 

  58. Krzeski P, Zych W, Kraszewska E, et al (1999) Is serum bili-rubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 30: 865–9

    Article  CAS  PubMed  Google Scholar 

  59. Lazaridis KN, Juran BD, Boe GM, et al (2007) Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 46: 785–92

    Article  PubMed  Google Scholar 

  60. Lee J, Belanger A, Doucette JT, et al (2007) Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 5: 1313–5

    Article  PubMed  Google Scholar 

  61. Leuschner M, Güldütüna S, You T, et al (1996) Ursodeo-xycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 25: 49–57

    Article  CAS  PubMed  Google Scholar 

  62. Leuschner M, Maier KP, Schlichting J, et al (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhois: results of a prospective double blind trial. Gastroenterology 117: 918–25

    Article  CAS  PubMed  Google Scholar 

  63. Leuschner M, Dietrich CF, You T, et al (2000) Characterization of patients with primary biliary cirrhosis responding to long-term ursodeoxycholic acid therapy. Gut 46: 121–6

    Article  CAS  PubMed  Google Scholar 

  64. Leuschner U, Güldütüna S, Imhof M, et al (1994) Effect of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 21: 624–33

    Article  CAS  PubMed  Google Scholar 

  65. Levy C, Zein CO, Gomez J, et al (2007) Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 5: 803–8

    Article  PubMed  Google Scholar 

  66. Lindor KD, Dickson ER, Jorgensen RA, et al (1995) The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 22: 1158–62

    CAS  PubMed  Google Scholar 

  67. Lindor KD, Hoofnagle J, Maddrey WC, et al (1996) Primary biliary cirrhosis clinical research single-topic conference. Hepatology 23: 639–44

    Article  CAS  PubMed  Google Scholar 

  68. Lindor KD, Therneau TM, Jorgensen RA, et al (1996) Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110: 1515–18

    Article  CAS  PubMed  Google Scholar 

  69. Locke GR III, Therneau TM, Ludwig J, et al (1996) Time course of histological progression in primary biliary cirrhosis. Hepatology 23: 52–6

    Article  PubMed  Google Scholar 

  70. Lombard M, Portmann B, Neuberger J (1993) Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104: 519–26

    CAS  PubMed  Google Scholar 

  71. Longo M, Crosignani A, Battezzati PM, et al (2002) Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51: 265–9

    Article  CAS  PubMed  Google Scholar 

  72. Ludwig J, Dickson ER, McDonald GS (1978) Staging of nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379: 103–12

    Article  CAS  PubMed  Google Scholar 

  73. Mason AL, Xu L, Guo L, et al (1998) Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 351: 1620–4

    Article  CAS  PubMed  Google Scholar 

  74. Mason AL, Farr GH, Xu L, et al (2004) Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 99: 2348–55

    Article  CAS  PubMed  Google Scholar 

  75. Matsumura S, Van De Water J, Leung P, et al (2004) Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 39: 1415–22

    Article  CAS  PubMed  Google Scholar 

  76. Mendes FD, Kim WR, Pedersen R, et al (2008) Mortality attributable to cholestatic liver disease in the United States. Hepatology 47: 1241–7

    Article  PubMed  Google Scholar 

  77. Metcalf JV, Mitchison HC, Palmer JM, et al (1996) Natural history of early primary biliary cirrhosis. Lancet 348: 1399–402

    Article  CAS  PubMed  Google Scholar 

  78. Miozzo M, Selmi C, Gentilin B, et al (2007) Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 46: 456–62

    Article  CAS  PubMed  Google Scholar 

  79. Mitchison HC, Bassendine MF, Hendrick A, et al (1986) Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6: 1279–84

    Article  CAS  PubMed  Google Scholar 

  80. Mitchison HC, Palmer JM, Bassendine MF, et al (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15: 336–44

    Article  CAS  PubMed  Google Scholar 

  81. Muratori P, Muratori L, Ferrari R, et al (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98: 431–7

    Article  PubMed  Google Scholar 

  82. Muratori P, Muratori L, Gershwin ME, et al (2004) ‘True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol 135: 154–8

    Article  CAS  PubMed  Google Scholar 

  83. Nakamura M, Kondo H, Mori T, et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45: 118–27

    Article  CAS  PubMed  Google Scholar 

  84. Nakamura M, Shimizu-Yoshida Y, Takii Y, et al (2005) Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 42: 386–92

    Article  CAS  PubMed  Google Scholar 

  85. Nakanuma Y (1991) Pathology of septum formation in primary biliary cirrhosis: a histological study in the non-cir-rhotic stage. Virchows Arch A Pathol Anat Histopathol 419: 381–7

    Article  CAS  PubMed  Google Scholar 

  86. Neuberger J (2003) Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol 39: 142–8

    Article  PubMed  Google Scholar 

  87. Neuberger J, Thomson R (1999) PBC and AMA—What is the connection? Hepatology 29: 271–6

    Article  CAS  PubMed  Google Scholar 

  88. Newton JL, Allen J, Kerr S, et al (2006) Reduced heart rate variability and baroreflex sensitivity in primary biliary cirrhosis. Liver Int 26: 197–202

    Article  PubMed  Google Scholar 

  89. Newton JL, Davidson A, Kerr S, et al (2007) Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. Eur J Gastroenterol Hepatol 19: 125–32

    Article  PubMed  Google Scholar 

  90. Newton JL, Pairman J, Sutcliffe K, et al (2008) A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol 6: 228–33

    Article  PubMed  Google Scholar 

  91. Oertelt S, Rieger R, Selmi C, et al (2007) A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 45: 659–65

    Article  CAS  PubMed  Google Scholar 

  92. Papatheodoridis G V, Hadziyannis ES, Deutsch M, et al (2002) Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenetrol 97: 2063–70

    Article  CAS  Google Scholar 

  93. Parés A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterol-ogy 130: 715–20

    Article  CAS  Google Scholar 

  94. Parés A, Cisneros L, Salmeron JM, et al (2004) Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 99: 1105–10

    Article  PubMed  Google Scholar 

  95. Parés A, Rodes J (2003) Natural history of primary biliary cirrhosis. Clin Liver Dis 7: 779–94

    Article  PubMed  Google Scholar 

  96. Portmann B, Popper H, Neuberger J, et al (1985) Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 88: 1777–90

    CAS  PubMed  Google Scholar 

  97. Poupon RE, Bonnand AM, Chrétien Y, et al (1999) Ten-year survival in ursodesoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 29: 1668–71

    Article  CAS  PubMed  Google Scholar 

  98. Poupon RE, Poupon R, Balkau B, et al (1994) Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 330: 1342–7

    Article  CAS  PubMed  Google Scholar 

  99. Poupon RE, Lindor KD, Cauch-Dudek K, et al (1997) Combined analysis of randomized controlled trials of ursode-oxycholic acid in primary biliary cirrhosis. Gastroenterology 113: 884–90

    Article  CAS  PubMed  Google Scholar 

  100. Poupon RE, Lindor KD, Parés A, et al (2003) Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39: 12–6

    Article  CAS  PubMed  Google Scholar 

  101. Poupon RE, Chretien Y, Chazouilleres O, et al (2004) Quality of life in patients with primary biliary cirrhosis. Hepatology 40: 489–94

    Article  PubMed  Google Scholar 

  102. Poupon RE, Chazouilleres O, Corpechot C, et al (2006) Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 44: 85–90

    Article  PubMed  Google Scholar 

  103. Prince MI, Chetwynd A, Diggle P, et al (2001) The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 34: 1083–8

    Article  CAS  PubMed  Google Scholar 

  104. Prince MI, Chetwynd A, Newman W, et al (2002) Survival and symptom progression in a large geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123: 1044–51

    Article  PubMed  Google Scholar 

  105. Rautiainen H, Färkkila M, Neuvonen M, et al (2006) Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther 24: 1545–52

    Article  CAS  PubMed  Google Scholar 

  106. Rautiainen H, Karkkainen P, Karvonen AL, et al (2005) Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41: 747–752

    Article  CAS  PubMed  Google Scholar 

  107. Reddy A, Prince MI, James OF, et al (2004) Tamoxifen: a novel treatment for primary biliary cirrhosis? Liver Int 24: 194–7

    Article  CAS  PubMed  Google Scholar 

  108. Rigamonti C, Shand LM, Feudjo M, et al (2006) Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55: 388–94

    Article  CAS  PubMed  Google Scholar 

  109. Sayers TJ, Baum H (1976) Possible cross-reactivity of human anti-mitochondrial antibodies with membrane vesicles of Paracoccus denitrificans. Biochem Soc Trans 4: 138–9

    CAS  PubMed  Google Scholar 

  110. Scheuer PJ (1967) Primary biliary cirrhosis. Proc R Soc Med 60: 1257–60

    CAS  PubMed  Google Scholar 

  111. Selmi C, Balkwill DL, Invernizzi P, et al (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38: 1250–7

    Article  CAS  PubMed  Google Scholar 

  112. Selmi C, Zuin M, Bowlus CL, et al (2008) Anti-mitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis 12: 173–85

    Article  PubMed  Google Scholar 

  113. Serfaty L, De Leusse A, Rosmorduc, O et al (2003) Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 38: 203–9

    Article  CAS  PubMed  Google Scholar 

  114. Shapiro JM, Smith H, Schaffner F (1979) Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20: 137–40

    Article  CAS  PubMed  Google Scholar 

  115. Sherlock S (1959) Primary biliary cirrhosis (chronic intra-hepatic obstructive jaundice). Gastroenterology 37: 574–86

    CAS  PubMed  Google Scholar 

  116. Shi J, Wu C, Lin Y, et al (2006) Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastro-enterol 101: 1529–38

    Article  CAS  Google Scholar 

  117. Shibuya A, Tanaka K, Miyakawa H, et al (2002) Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35: 1172–8

    Article  PubMed  Google Scholar 

  118. Springer J, Cauch-Dudek K, O'Rourke K, et al (1999) Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 94: 47–53

    Article  CAS  PubMed  Google Scholar 

  119. Stanca CM, Bach N, Krause C, et al (2005) Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 100: 1104–9

    Article  PubMed  Google Scholar 

  120. Stojakovic T, Putz-Bankuti C, Fauler G, et al (2007) Ator-vastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776–84

    Article  CAS  PubMed  Google Scholar 

  121. Strassburg CP, Jaeckel E, Manns MP (1999) Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 11: 595–601

    Article  CAS  PubMed  Google Scholar 

  122. Suzuki A, Lymp J, Donlinger J (2007) Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 5: 259–64

    Article  CAS  PubMed  Google Scholar 

  123. Talwalkar JA, Donlinger JJ, Gossard AA, et al (2006) Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 51: 1985–91

    Article  CAS  PubMed  Google Scholar 

  124. Tanaka A, Borchers AT, Ishibashi H, et al (2001) Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol 96: 8–15

    Article  CAS  PubMed  Google Scholar 

  125. ter Borg PC, Schalm SW, Hansen BE, et al (2006) Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101: 2044–50

    Article  CAS  PubMed  Google Scholar 

  126. Terasaki S, Nakanuma Y, Yamazaki M, et al (1993) Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 17: 206–12

    Article  CAS  PubMed  Google Scholar 

  127. Theal JJ, Toosi MN, Girlan L, et al (2005) A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 41: 1305–12

    Article  CAS  PubMed  Google Scholar 

  128. Tinmouth J, Lee M, Wanless IR, et al (2002) Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 22: 228–34

    Article  PubMed  Google Scholar 

  129. Van Norstrand MD, Malinchoc M, Lindor KD, et al (1975) Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 25: 6–11

    Article  Google Scholar 

  130. van Os E, van den Broek WW, Mulder PG, et al (2007) Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 46: 1099–103

    Article  PubMed  Google Scholar 

  131. Vleggaar FP, van Buuren HR, Zondervan PE, et al (2001) Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 49: 276–81

    Article  CAS  PubMed  Google Scholar 

  132. Walker JG, Doniach D, Roitt IM, et al (1965) Anti-mitochondrial antibodies in primary biliary cirrhosis. Lancet i: 827–31

    Article  Google Scholar 

  133. Washington K, Clavien PA, Killenberg P (1997) Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum Pathol 28: 791–5

    Article  CAS  PubMed  Google Scholar 

  134. Wesierska-Gadek J, Penner E, Battezzati PM, et al (2006) Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43: 1135–44

    Article  CAS  PubMed  Google Scholar 

  135. Wolfhagen FHJ, van Hoogstraten HJF, van Buuren HR, et al (1998) Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 29: 736–42

    Article  CAS  PubMed  Google Scholar 

  136. Xu L, Sakalian M, Shen Z, et al (2004) Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 39: 151–6

    Article  CAS  PubMed  Google Scholar 

  137. Xu L, Shen S, Guo L, et al (2003) Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA 100: 8454–9

    Article  CAS  PubMed  Google Scholar 

  138. Yamazaki A, Suzuki K, Nakamura A, et al (1999) Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 30: 71–8

    Article  CAS  PubMed  Google Scholar 

  139. Yang WH, Yu JH, Nakajima A, et al (2004) Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2: 1116–22

    Article  PubMed  Google Scholar 

  140. Zein CO, Beatty K, Post AB, et al (2006) Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 44: 1564–71

    Article  CAS  PubMed  Google Scholar 

  141. Zein CO, Jorgensen RA, Clarke B, et al (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. Hepatology 42: 762–71

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair, Department of Medicine II, Klinikum Offenbach, Goethe University Frankfurt/Main, Starkenburgring 66, Offenbach, 63069, Germany

    Henryk Dancygier (Professor of Medicine)

  2. Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA

    Henryk Dancygier (Professor of Medicine)

Authors
  1. Henryk Dancygier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dancygier, H. (2010). Primary Biliary Cirrhosis. In: Clinical Hepatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04519-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04519-6_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04509-7

  • Online ISBN: 978-3-642-04519-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation